ONON - Morgan Stanley screens 10 most unappreciated post-COVID stocks

"In our view, it's not a transitory 'Covid Bump' for these 10 stocks," Morgan Stanley says. "Many companies garnered outsized boosts to revenues in 2020 and 2021, as their business models were leveraged to the sharp changes in the economy and consumer behavior during the peaks of the pandemic, and saw their shares perform strongly as a result." Morgan's equity strategy team said in a note they have "observed that some stocks have underperformed in recent months amid market fears these companies only did well amidst the Covid pandemic." "Our analysts view these names not as narrowly-defined Covid beneficiaries but instead as solid businesses that are structurally positioned for long-term outperformance. We believe this disconnect has left many of them at a meaningful discount to intrinsic value." The stocks are: Bath & Body Works (BBWI): "This topline growth and margin profile is best-in-class amongst our coverage. But BBWI currently trades at

For further details see:

Morgan Stanley screens 10 most unappreciated post-COVID stocks